Heron Therapeutics reports fourth-quarter, full-year 2023 financial results
Click Here to Manage Email Alerts
Key takeaways:
- Heron Therapeutics reported its fourth-quarter and full-year 2023 financial results.
- The company achieved a quarterly record of $5.6 million in net product sales from Zynrelef in the fourth quarter.
Heron Therapeutics Inc. reported its fourth-quarter and full-year 2023 financial results, according to a press release.
Heron Therapeutics achieved a quarterly record of $5.6 million in net product sales from Zynrelef for the fourth quarter of 2023. The company also reported $107.9 million in revenue from its oncology care franchise. According to the release, the company reaffirmed its full-year 2024 financial guidance for product revenues, net, adjusted operating expenses and adjusted earnings before interest, taxes, depreciation and amortization.
“In the fourth quarter of 2023, Heron saw continued positive momentum and an increased sales trajectory in both our acute care and oncology care franchises, illustrating how the strategic decisions made over the past year have positioned the company for long-term success and profitability,” Craig Collard, CEO of Heron Therapeutics, said in the release. “I am pleased to share this quarterly update and look forward to building upon what we achieved in the fourth quarter of 2023, providing substantial value and meaningful solutions in the acute care and oncology care settings.”
Read more about
Click Here to Manage Email Alerts